Skip to main content

Table 3 Clinicopathologic characteristics of the patients who did not receive secondary debulking surgery

From: Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

Characteristics All (n = 118) Extended chemotherapy (n = 51) Standard chemotherapy (n = 67) P
Age at initial diagnosis, years 56.1 ± 10.0 54.8 ± 9.0 57.1 ± 10.6 0.208
Age at 1st recurrence, years 57.9 ± 9.9 56.4 ± 9.0 59.0 ± 10.5 0.159
Primary site of disease     0.499
 Ovary 107 (90.7) 45 (88.2) 62 (92.5)  
 Tube 3 (2.5) 1 (2.0) 2 (3.0)  
 Peritoneum 8 (6.8) 5 (9.8) 3 (4.5)  
Histologic type     0.381
 Serous 106 (89.8) 46 (90.2) 60 (89.6)  
 Endometrioid 6 (5.1) 3 (5.9) 3 (4.5)  
 Mucinous 3 (2.5) 2 (3.9) 1 (1.5)  
 Clear cell 3 (2.5) 0 3 (4.5)  
 Mixed     
Grade     0.113
 1 2 (1.7) 2 (3.9) 0  
 2 6 (5.1) 1 (2.0) 5 (7.5)  
 3 110 (93.2) 48 (94.1) 62 (92.5)  
FIGO stage     0.686
 I-II 7 (5.9) 4 (7.8) 3 (4.5)  
 III 78 (66.1) 34 (66.7) 44 (65.7)  
 IV 33 (28.0) 13 (25.5) 20 (29.9)  
Primary treatment strategy     0.625
 PDS 86 (72.9) 36 (70.6) 50 (74.6)  
 NAC 32 (27.1) 15 (29.4) 17 (25.4)  
Results of initial debulking surgery     0.036
 Complete gross resection 59 (50.0) 21 (41.2) 38 (56.7)  
 Residual tumor <1 cm 32 (27.1) 20 (39.2) 12 (17.9)  
 Residual tumor ≥1 cm 27 (22.9) 10 (19.6) 17 (25.4)  
Platinum-free interval, months
 Median (range) 12.2 (6.0–87.9) 11.0 (6.2–87.9) 12.7 (6.0–57.8) 0.059
 6–12, partially platinum-sensitive 55 (46.6) 27 (52.9) 28 (41.8) 0.229
 ≥12, totally platinum-sensitive 63 (53.4) 24 (47.1) 39 (58.2)  
CA-125 at 1st recurrence, IU/mL     0.145
 Median (range) 93.3 (7.9–6290.0) 107.9 (12.0–6290.0) 92.9 (7.9–1908.0)  
Residual tumor on CT after #6     0.446
 ≥0.5 cm and <1 cm 57 (48.3) 27 (52.9) 30 (44.8)  
 ≥1 cm and <2 cm 47 (39.8) 17 (33.3) 30 (44.8)  
 ≥2 cm 14 (11.9) 7 (13.7) 7 (10.4)  
CA-125 after #6, IU/mL     0.087
 Median (range) 12.7 (1.1–289.7) 14.0 (1.1–249.0) 11.0 (1.1–289.7)  
Maintenance therapy
 No 90 (76.3) 45 (88.2) 45 (67.2) 0.008
 Yes 28 (23.7) 6 (11.8) 22 (32.8)  
 Bevacizumab 23 (19.5) 5 (9.8) 18 (26.9) >0.999
 Olaparib 5 (4.2) 1 (2.0) 4 (6.0)  
Germline BRCA1/2 gene test
 Not performed 49 (41.5) 23 (45.1) 26 (38.8) 0.492
 Performed 69 (58.5) 28 (54.9) 41 (61.2)  
 Wild-type 47 (39.8) 20 (39.2) 27 (40.3) 0.626
 Mutation 22 (18.6) 8 (15.7) 14 (20.9)  
  1. Values are presented as mean ± standard deviation or n (%) unless otherwise indicated
  2. Abbreviations: CA-125 Cancer antigen 125, CT Computed tomography, FIGO International Federation of Gynecology and Obstetrics